These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8173946)

  • 1. Intracerebroventricular neuropeptide Y increases gastric acid secretion by decreasing tonic adrenergic inhibition of acid in dogs.
    Geoghegan JG; Lawson DC; Cheng CA; Pappas TN
    Brain Res; 1994 Jan; 635(1-2):118-24. PubMed ID: 8173946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of neuropeptide Y and [Leu31,Pro34] neuropeptide Y on experimental gastric lesion formation and gastric secretion in the rat.
    Penner SB; Smyth DD; Glavin GB
    J Pharmacol Exp Ther; 1993 Jul; 266(1):339-43. PubMed ID: 8101219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats.
    Gué M; Junien JL; Reeve JR; Rivier J; Grandt D; Taché Y
    Br J Pharmacol; 1996 May; 118(2):237-42. PubMed ID: 8735621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptide Y functions as a physiologic regulator of cephalic phase acid secretion.
    Lee MC; Lawson DC; Pappas TN
    Regul Pept; 1994 Aug; 52(3):227-34. PubMed ID: 7800854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracerebroventricular neuropeptide Y increases gastric and pancreatic secretion in the dog.
    Geoghegan JG; Lawson DC; Cheng CA; Opara E; Taylor IL; Pappas TN
    Gastroenterology; 1993 Oct; 105(4):1069-77. PubMed ID: 8405851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropeptide Y produces anxiety via Y2-type receptors.
    Nakajima M; Inui A; Asakawa A; Momose K; Ueno N; Teranishi A; Baba S; Kasuga M
    Peptides; 1998; 19(2):359-63. PubMed ID: 9493869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antinociceptive effects of neuropeptide Y and related peptides in mice.
    Broqua P; Wettstein JG; Rocher MN; Gauthier-Martin B; Riviere PJ; Junien JL; Dahl SG
    Brain Res; 1996 Jun; 724(1):25-32. PubMed ID: 8816252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central neuropeptide Y and the sigma ligand, JO 1784, reverse corticotropin-releasing factor-induced inhibition of gastric acid secretion in rats.
    Gué M; Yoneda M; Mönnikes H; Junien JL; Taché Y
    Br J Pharmacol; 1992 Nov; 107(3):642-7. PubMed ID: 1472962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the Y-1 receptor subtype in the regulation of luteinizing hormone secretion by neuropeptide Y in rats.
    Kalra SP; Fuentes M; Fournier A; Parker SL; Crowley WR
    Endocrinology; 1992 Jun; 130(6):3323-30. PubMed ID: 1317781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y and [Leu31,Pro34]neuropeptide Y potentiate potassium-induced noradrenaline release in the paraventricular nucleus of the aged rat.
    Hastings JA; Pavia JM; Morris MJ
    Brain Res; 1997 Mar; 750(1-2):301-4. PubMed ID: 9098556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of neuropeptide Y on growth hormone secretion in rats is mediated by both Y1- and Y2-receptor subtypes and abolished after anterolateral deafferentation of the medial basal hypothalamus.
    Suzuki N; Okada K; Minami S; Wakabayashi I
    Regul Pept; 1996 Sep; 65(2):145-51. PubMed ID: 8884982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
    Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
    Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sympathetic and parasympathetic interaction in vascular and secretory control of the nasal mucosa in anaesthetized dogs.
    Revington M; Lacroix JS; Potter EK
    J Physiol; 1997 Dec; 505 ( Pt 3)(Pt 3):823-31. PubMed ID: 9457655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Leu31,Pro34]neuropeptide Y (NPY), but not NPY 20-36, produces discriminative stimulus effects similar to NPY and induces food intake.
    Jewett DC; Cleary J; Schaal DW; Thompson T; Levine AS
    Brain Res; 1993 Dec; 631(1):129-32. PubMed ID: 8298985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation by neuropeptide Y of parasympathetic nerve-evoked nasal vasodilatation via Y2 prejunctional receptor.
    Lacroix JS; Ulman LG; Potter EK
    Br J Pharmacol; 1994 Oct; 113(2):479-84. PubMed ID: 7834199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural requirements for the effects of neuropeptide Y on the hypothalamic-pituitary-adrenal axis in the dog.
    Miura M; Inui A; Teranishi A; Hirosue Y; Nakajima M; Okita M; Inoue T; Baba S; Kasuga M
    Neuropeptides; 1992 Sep; 23(1):15-8. PubMed ID: 1328925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release.
    Small CJ; Morgan DG; Meeran K; Heath MM; Gunn I; Edwards CM; Gardiner J; Taylor GM; Hurley JD; Rossi M; Goldstone AP; O'Shea D; Smith DM; Ghatei MA; Bloom SR
    Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11686-91. PubMed ID: 9326671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Centrally administered NPY stimulated gastric acid and pepsin secretion by a vagally mediated mechanism.
    Matsuda M; Aono M; Moriga M; Okuma M
    Regul Pept; 1991 Jul; 35(1):31-41. PubMed ID: 1924894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.
    Palea S; Corsi M; Rimland JM; Trist DG; Ratti E
    Br J Pharmacol; 1995 Nov; 116(5):2401-6. PubMed ID: 8581275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically significant effect of neuropeptide Y to suppress growth hormone release by stimulating somatostatin discharge.
    Rettori V; Milenkovic L; Aguila MC; McCann SM
    Endocrinology; 1990 May; 126(5):2296-301. PubMed ID: 1970290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.